Literature DB >> 8622912

Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production.

C S Hirsch1, R Hussain, Z Toossi, G Dawood, F Shahid, J J Ellner.   

Abstract

In tuberculosis, Mycobacterium tuberculosis (MTB)-stimulated T-cell responses are depressed transiently, whereas antibody levels are increased. Lymphoproliferative responses of peripheral blood mononuclear cells (PBMCs) from Pakistani tuberculosis (TB) patients to both mycobacterial and candidal antigens were suppressed by approximately 50% when compared to healthy purified protein derivative (PPD)-positive household contacts. Production of interferon gamma (IFN-gamma) in response to PPD also was depressed by 78%. Stimulation with PPD and the 30-kDa alpha antigen of MTB (30-kDa antigen) induced greater secretion of transforming growth factor beta (TGF-beta), but not interleukin 10 (IL-10) or tumor necrosis factor alpha (TNF-alpha), by PBMCs from TB patients compared to healthy contacts. The degree of suppression correlated with the duration of treatment; patients treated for <1 month had significantly lower T-cell blastogenesis and IFN-gamma production and higher levels of TGF-beta than did patients treated for >1 month. Neutralizing antibody to TGF-beta normalized lymphocyte proliferation in response to PPD, partially restored blastogenesis to candidal antigen, and significantly increased PPD-stimulated production of IFN-gamma in TB patients but not in contacts. Neutralizing antibody to IL-10 augmented, but did not normalize, T-cell responses to both PPD and candida in TB patients and candidal antigen in contacts. TGF-beta, produced in response to MTB antigens, therefore plays a prominent role in down-regulating potentially protective host effector mechanisms and looms as an important mediator of immunosuppression in TB.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622912      PMCID: PMC39581          DOI: 10.1073/pnas.93.8.3193

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Transforming growth factor beta downregulates interleukin-1 (IL-1)-induced IL-6 production by human monocytes.

Authors:  T Musso; I Espinoza-Delgado; K Pulkki; G L Gusella; D L Longo; L Varesio
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

2.  Pleural fluid and peripheral blood lymphocyte function in tuberculosis.

Authors:  J J Ellner
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

3.  Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot.

Authors:  R S Wallis; M Amir-Tahmasseb; J J Ellner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

4.  Cytokine production at the site of disease in human tuberculosis.

Authors:  P F Barnes; S Lu; J S Abrams; E Wang; M Yamamura; R L Modlin
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

5.  Immunoreactivity of a 10-kDa antigen of Mycobacterium tuberculosis.

Authors:  P F Barnes; V Mehra; B Rivoire; S J Fong; P J Brennan; M S Voegtline; P Minden; R A Houghten; B R Bloom; R L Modlin
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

6.  Cytokine patterns in the pathogenesis of human leishmaniasis.

Authors:  C Pirmez; M Yamamura; K Uyemura; M Paes-Oliveira; F Conceição-Silva; R L Modlin
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.

Authors:  T Espevik; I S Figari; G E Ranges; M A Palladino
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

8.  A role for transforming growth factor-beta 1 in regulating natural killer cell and T lymphocyte proliferative responses during acute infection with lymphocytic choriomeningitis virus.

Authors:  H C Su; K A Leite-Morris; L Braun; C A Biron
Journal:  J Immunol       Date:  1991-10-15       Impact factor: 5.422

9.  Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation.

Authors:  S M Wahl; D A Hunt; H L Wong; S Dougherty; N McCartney-Francis; L M Wahl; L Ellingsworth; J A Schmidt; G Hall; A B Roberts
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

10.  Specific lymphoproliferation, gamma interferon production, and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis.

Authors:  K Huygen; J P Van Vooren; M Turneer; R Bosmans; P Dierckx; J De Bruyn
Journal:  Scand J Immunol       Date:  1988-02       Impact factor: 3.487

View more
  63 in total

1.  Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor-alpha (TNF-alpha) and IL-6 but not anti-inflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes-implications for pathogenesis.

Authors:  R Hussain; H Shiratsuchi; M Phillips; J Ellner; R S Wallis
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

2.  Latency-associated peptide of transforming growth factor beta enhances mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL/6 mice.

Authors:  K A Wilkinson; T D Martin; S M Reba; H Aung; R W Redline; W H Boom; Z Toossi; S A Fulton
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 3.  Tuberculosis: latency and reactivation.

Authors:  J L Flynn; J Chan
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

4.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 5.  Immunoregulation in TB: observations and implications.

Authors:  Jerrold J Ellner
Journal:  Clin Transl Sci       Date:  2010-02       Impact factor: 4.689

6.  Invasive candidiasis stimulates hepatocyte and monocyte production of active transforming growth factor beta.

Authors:  J J Letterio; T Lehrnbecher; G Pollack; T J Walsh; S J Chanock
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  Evaluation of the recombinant 38-kilodalton antigen of Mycobacterium tuberculosis as a potential immunodiagnostic reagent.

Authors:  R J Wilkinson; K Hasløv; R Rappuoli; F Giovannoni; P R Narayanan; C R Desai; H M Vordermeier; J Paulsen; G Pasvol; J Ivanyi; M Singh
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

8.  Intestinal helminth co-infection has a negative impact on both anti-Mycobacterium tuberculosis immunity and clinical response to tuberculosis therapy.

Authors:  T Resende Co; C S Hirsch; Z Toossi; R Dietze; R Ribeiro-Rodrigues
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

9.  38 000 MW antigen-specific major histocompatibility complex class I restricted interferon-gamma-secreting CD8+ T cells in healthy contacts of tuberculosis.

Authors:  R J Wilkinson; X Zhu; K A Wilkinson; A Lalvani; J Ivanyi; G Pasvol; H M Vordermeier
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

10.  Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis.

Authors:  R A Fabre; T M Pérez; L D Aguilar; M J Rangel; I Estrada-Garcìa; R Hernández-Pando; S Estrada Parra
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.